Paul Reider's Insider Trades & SAST Disclosures
Paul Reider's most recent trade in Coherus Biosciences Inc was a trade of 4,858 Common Stock done at an average price of $1.4 . Disclosure was reported to the exchange on Jan. 20, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Paul Reider.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Coherus Biosciences Inc | Paul Reider | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.39 per share. | 20 Jan 2025 | 4,858 | 82,069 (0%) | 0% | 1.4 | 6,753 | Common Stock |
| Coherus Biosciences Inc | Paul Reider | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 160,000 | 160,000 | - | - | Stock Option (Right to Buy) | |
| Coherus Biosciences Inc | Paul Reider | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.66 per share. | 03 Jan 2025 | 2,277 | 86,927 (0%) | 0% | 1.7 | 3,780 | Common Stock |
| Coherus Biosciences Inc | Paul Reider | Chief Commercial Officer | 13 Dec 2024 | 2,073 | 89,204 (0%) | 0% | 1.6 | 3,338 | Common Stock | |
| Coherus Biosciences Inc | Paul Reider | Chief Commercial Officer | 22 Jul 2024 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | ||
| Coherus Biosciences Inc | Paul Reider | Chief Commercial Officer | 20 Jan 2024 | 4,854 | 81,277 (0%) | 0% | 2.4 | 11,844 | Common Stock | |
| Coherus Biosciences Inc | Paul Reider | Chief Commercial Officer | 04 Jan 2024 | 2,275 | 86,131 (0%) | 0% | 2.9 | 6,643 | Common Stock | |
| Coherus Biosciences Inc | Reider Paul | Chief Commercial Officer | 02 Jan 2024 | 160,000 | 160,000 | - | - | Stock Option (Right to Buy) | ||
| Coherus Biosciences Inc | Reider Paul | Chief Commercial Officer | 13 Dec 2023 | 2,049 | 88,406 (0%) | 0% | 2.4 | 4,856 | Common Stock | |
| Coherus Biosciences Inc | Paul Reider | Chief Commercial Officer | 13 Jun 2023 | 70,000 | 70,000 | - | - | Stock Option (Right to Buy) | ||
| Coherus Biosciences Inc | Paul Reider | Chief Commercial Officer | 01 Apr 2023 | 2,451 | 87,053 (0%) | 0% | 6.8 | 16,765 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges